Can study participants receive supportive therapies such as Procrit® (epoetin alfa) or Neumega® (oprelvekin) during the study?
While the use of Procrit or Neumega is not specifically prohibited, if a patient were to require such supportive therapy, his/her cancer would probably have progressed to the point where other anti-leukemic therapy(ies) would be necessary. In this case, he/she would no longer be eligible for participation in this study and would not be able to receive any further immunizations of MyVax® Personalized Immunotherapy.
